Quarter Comparison

Vivos Therapeutics, Inc. logo
Vivos Therapeutics, Inc.— Sankey Diagram

Quarterly mode · period ending 2025-12-31 · View 10-Q on SEC EDGAR

ComparingFY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)
Revenue
$17M
↑+16.0% +$2Mvs FY2024 (Q1+Q2+Q3+Q4)
Gross Profit
$11M
↑+16.9% +$2Mvs FY2024 (Q1+Q2+Q3+Q4)
Operating profit
$8M
↑+1.1% +$92Kvs FY2024 (Q1+Q2+Q3+Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the quarterly mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2025 (Q1+Q2+Q3+Q4)FY2024 (Q1+Q2+Q3+Q4)
Revenue$17M$15M
COGS$7M$6M
Gross Profit$11M$9M
R&D$0$100K
SG&A$0$0
D&A$1M$581K
Other OpEx$846K$41K
Operating Income$8M$8M
Interest Exp.$1M$8M
Other Non-Op$7M$0
Pretax Income$0$0
Tax$0$0
Net Income$0$0

QuarterCharts · SEC EDGAR data · VVOS · Comparing FY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)